Lexicon Pharmaceuticals (LXRX) Share-based Compensation (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Share-based Compensation data on file, last reported at $3.1 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $3.1 million, up 1.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.3 million (up 20.74% YoY), and the FY2025 annual result was $12.5 million, down 7.27% from the prior year.
• Share-based Compensation climbed to $3.1 million in Q1 2026 per LXRX's latest filing, from $2.8 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $4.3 million in Q1 2024 and troughed at $939000.0 in Q3 2022.
• A 5-year average of $2.5 million and a median of $2.8 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation sank 65.38% in 2022, then surged 172.74% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $3.3 million in 2022, then decreased by 1.71% to $3.2 million in 2023, then plunged by 52.15% to $1.5 million in 2024, then surged by 84.45% to $2.8 million in 2025, then climbed by 8.57% to $3.1 million in 2026.
• Business Quant data shows LXRX's Share-based Compensation at $3.1 million in Q1 2026, $2.8 million in Q4 2025, and $1.8 million in Q3 2025.